Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/ml, TROP2 Ka of 0.3083 nM, and topoisomerase I IC50 of 0.7 µmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer[1][2][3].
Molecular Weight:
157907 (average)
Purity:
99.63
CAS Number:
[2768350-77-0]
Target:
Antibody-Drug Conjugates (ADCs),TROP2
Application Notes:
MCE Product type: ADC Related
* VAT and and shipping costs not included. Errors and price changes excepted
